Replimune Shares Approach a Pivotal Regulatory Verdict

FDA to decide on Replimune's melanoma therapy RP1 on April 10. Company secured funding through 2027 as trading volume spikes ahead of the high-stakes verdict.

Investors are closely monitoring Replimune Group Inc. as the biopharmaceutical company approaches a critical regulatory milestone. The U.S. Food and Drug Administration (FDA) is set to announce its decision on the approval of the cancer therapy RP1 on April 10. This follows a complete response letter issued by the agency last year, making this second review a high-stakes event for the firm.

Financial Runway and Strategic Funding

Ahead of this decision, Replimune has fortified its balance sheet. The company amended an existing credit agreement with Hercules Capital, securing an immediate $35 million. An additional $120 million in potential funding is contingent upon achieving specific milestones post-approval. Management states that with current cash and equivalents of approximately $269 million, its operational funding is secure through the first quarter of 2027.

Trading Activity Reflects Mounting Anticipation

Market activity has intensified significantly in the lead-up to the FDA's deadline. Recent trading sessions saw volume spike to as high as 2.8 million shares, more than double the stock's average daily volume. Share prices climbed to $7.65 by the close of the first quarter, reflecting heightened volatility and investor speculation surrounding the pending announcement. The application under review seeks approval for RP1 in combination with nivolumab to treat patients with advanced melanoma.

Addressing Prior FDA Concerns

The current review stems from a resubmission filed in October 2025. This action was necessary after the FDA declined to approve the therapy in July of the prior year, citing that the data from the IGNYTE clinical trial did not provide sufficient evidence of effectiveness. In response, CEO Sushil Patel submitted additional clinical analyses aimed at addressing the regulator's concerns.

Key data points from the IGNYTE study include:
- Overall Response Rate (ORR): 32.9%
- Complete Response Rate: 15.0%
- Incidence of Grade 3/4 Adverse Events: 12.9%
- Treatment-Related Deaths: 0

Looking Beyond the Immediate Decision

While the April 10 verdict will undoubtedly dictate the stock's near-term trajectory, Replimune is concurrently advancing its long-term strategy. The company is already progressing the Phase 3 confirmatory trial, IGNYTE-3, which aims to enroll approximately 400 patients. This study is designed to substantiate RP1's market position should it gain initial approval.